Elena Petre

Dr. Elena Petre


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
EPElena Petre
Elena Petre
XJXiaoyu Jia
Xiaoyu Jia
RTRaymond H. Thornton
Raymond H. Thornton
CSConstantinos T. Sofocleous
Constantinos T. Sofocleous
WAWilliam Alago
William Alago
SSStephen B. Solomon
Stephen B. Solomon

3 February 2017 in Visceral Medicine
Verified
Journal Article
Open access
PDF file
EPElena Petre
Elena Petre
CSConstantinos Sofocleous
Constantinos Sofocleous
Background: Surgical resection of limited colorectal liver disease improves long-term survival and can be curative in a subset of selected cases. Image-guided percutaneous ablation therapies have emerged as safe and effective alternative options for selected patients with unresectable colorectal liver metastases (CLM) that can be ablated with margins. Ablation causes focal destruction of tissue and has increasingly been shown to provide durable eradication of tumors. Methods: A selective review of literature was conducted in PubMed, focusing on recent studies reporting on the safety, efficacy, and long-term outcomes of percutaneous ablation modalities in the treatment of CLM. The present work gives an overview of the different ablation techniques, their current clinical indications, and reported outcomes from most recently published studies. The ‘test of time' concept for using ablation as a first local therapy is also described. Results: There are several thermal ablative tools currently available, including radiofrequency ablation (RFA), microwave ablation, and cryoablation. Most data to date originated from the application of RFA. Adjuvant thermal ablation in the treatment of oligometastatic colon cancer liver disease offers improved oncologic outcomes. The ideal CLM amenable to percutaneous ablation is a solitary tumor with the largest diameter up to 3 cm that can be completely ablated with a sufficient margin. 5-year overall survival rates up to 70% after ablation of unresectable CLM have been reported. Pathologic confirmation of complete tumor necrosis with margins over 5 mm provides best long-term local tumor control by thermal ablation. Conclusion: Current evidence suggests that percutaneous ablation as adjuvant to chemotherapy improves oncologic outcomes of patients with CLM. For small tumors that can be ablated completely with clear margins, percutaneous ablation may offer outcomes similar to those of surgery.

29 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NKNikiforos Vasiniotis Kamarinos
Nikiforos Vasiniotis Kamarinos
EVEfsevia (Evi) Vakiani
Efsevia (Evi) Vakiani
MGMithat Gonen
Mithat Gonen
NKNancy E. Kemeny
Nancy E. Kemeny
CSCarlie S. Sigel
Carlie S. Sigel
Constantinos T. SofocleousConstantinos T. Sofocleous
Constantinos T. Sofocleous
Background: Thermal ablation is a definitive local treatment for selected colorectal liver metastases (CLM) that can be ablated with adequate margins. A critical limitation has been local tumor progression (LTP). Methods: This prospective, single-group, phase 2 study enrolled patients with CLM < 5 cm in maximum diameter, at a tertiary cancer center between November 2009 and February 2019. Biopsy of the ablation zone center and margin was performed immediately after ablation. Viable tumor in tissue biopsy and ablation margins < 5 mm were assessed as predictors of 12-month LTP. Results: We enrolled 107 patients with 182 CLMs. Mean tumor size was 2.0 (range, 0.6–4.6) cm. Microwave ablation was used in 51% and radiofrequency ablation in 49% of tumors. The 12- and 24-month cumulative incidence of LTP was 22% (95% confidence interval [CI]: 17, 29) and 29% (95% CI: 23, 36), respectively. LTP at 12 months was 7% (95% CI: 3, 14) for the biopsy tumor-negative ablation zone with margins ≥ 5 mm vs. 63% (95% CI: 35, 85) for the biopsy-positive ablation zone with margins < 5 mm (p < 0.001). Conclusions: Biopsy-proven complete tumor ablation with margins of at least 5 mm achieves optimal local tumor control for CLM, regardless of the ablation modality used.

17 December 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
STSanjit O. Tewari
Sanjit O. Tewari
GGGeorge I. Getrajdman
George I. Getrajdman
EPElena Petre
Elena Petre
CSConstantinos T. Sofocleous
Constantinos T. Sofocleous
RSRobert H. Siegelbaum
Robert H. Siegelbaum
RTRaymond H. Thornton
Raymond H. Thornton

2 April 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
CRCarole A. Ridge
Carole A. Ridge
MSMikhail Silk
Mikhail Silk
EPElena Petre
Elena Petre
JEJoseph Erinjeri
Joseph Erinjeri
WAWilliam Alago
William Alago
SSStephen B. Solomon
Stephen B. Solomon

19 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MZMahdi Zirakchian Zadeh
Mahdi Zirakchian Zadeh
RYRandy Yeh
Randy Yeh
HKHenry S. Kunin
Henry S. Kunin
AKAssen S. Kirov
Assen S. Kirov
EPElena Petre
Elena Petre
Constantinos T. SofocleousConstantinos T. Sofocleous
Constantinos T. Sofocleous
Background: Real-time split-dose PET can identify the targeted colorectal liver metastasis (CLM) and eliminate the need for repeated contrast administration before and during thermal ablation (TA). This study aimed to assess the added value of pre-ablation real-time split-dose PET when combined with non-contract CT in the detection of CLM for ablation and the evaluation of the ablation zone and margins. Methods: A total of 190 CLMs/125 participants from two IRB-approved prospective clinical trials using PET/CT-guided TA were analyzed. Based on detection on pre-TA imaging, CLMs were categorized as detectable, non-detectable, and of poor conspicuity on CT alone, and detectable, non-detectable, and low FDG-avidity on PET/CT after the initial dose. Ablation margins around the targeted CLM were evaluated using a 3D volumetric approach. Results: We found that 129/190 (67.9%) CLMs were detectable on CT alone, and 61/190 CLMs (32.1%) were undetectable or of poor conspicuity, not allowing accurate depiction and targeting by CT alone. Thus, the theoretical 5- and 10-mm margins could not be defined in these tumors (32.1%) using CT alone. When TA intraprocedural PET/CT images are obtained and inspected (fused PET/CT), only 4 CLM (2.1%) remained undetectable or had a low FDG avidity. Conclusions: The addition of PET to non-contrast CT improved CLM detection for ablation targeting, margin assessments, and continuous depiction of the FDG avid CLMs during the ablation without the need for multiple intravenous contrast injections pre- and intra-procedurally.